Company continues remarkable growth in 2019, fueled by new product launches, the acquisition of UmanDiagnostics, further validation in ground-breaking publications and rapid adoption of digital biomarkers in neurology and oncology research
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its President, Chairman and Chief Executive Officer, Kevin Hrusovsky, will be presenting on the company’s growth and vision for the fourth consecutive year at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. Hrusovsky’s session will take place on Wednesday, Jan. 15, 2020 at 4 p.m., PST (7 p.m., EST) in California East, Westin St. Francis, with a Q&A session directly following at 4:30 p.m., PST (7:30 p.m., EST) in the Yorkshire Room, Westin St. Francis.
In the two years since the Company’s very successful initial public offering, Quanterix has continued to achieve accelerated double-digit, year-over-year growth in each full quarter. The Company has had several critical milestones and achievements, including strategic acquisitions and agreements, multiple product launches that build on the renowned Simoa technology platform, new additions to its leadership team, raised nearly $120 million in 2019, continued growing in scientific publications and expanded the biomarker menu.
"Our team is relentless in its drive to change how researchers and pharmaceutical companies approach drug development and early disease detection using biomarkers," said Hrusovsky. "Our customers and collaborators have made strong strides across neurology, with a groundswell of groundbreaking research validating neurofilament light (Nf-L) as a blood-based biomarker for measuring neurodegeneration. Oncology is witnessing a similar opportunity with Simoa. We are excited to discuss the unprecedented opportunity we have before us in the research markets and ultimately clinical diagnostic markets."
Significant 2019 Achievements:
- Launched the Simoa HD-X Analyzer, which delivers improved flexibility and sensitivity across a broad assay menu to empower more efficient and accurate biomarker analysis. Built upon the Company’s flagship Simoa HD-1 platform, HD-X shipments began one quarter ahead of schedule following a successful Early Access Program. Customer feedback on the HD-X has been positive with the instrument delivering a five-fold improvement in operational efficiency along with other key enhancements.
- Raised an aggregate of $119 million in gross proceeds via an at-the-market equity (ATM) facility and a follow-on primary offering to fuel further innovation and commercial growth.
- Acquired UmanDiagnostics AB, the preeminent developer of Nf-L protein antibodies. The acquisition positioned Quanterix to fully support and capitalize on the growing opportunities for Nf-L detection as it relates to the diagnosis, prognosis and monitoring of a wide range of conditions including Alzheimer’s disease, MS, Parkinson’s disease, traumatic brain injury, ALS, Huntington’s disease and others. This acquisition protects the Company’s strong leading Nf-L position and enhances its growth outlook.
- Powered more than 85 percent of the Nf-L biomarker research presented at the American Academy of Neurology’s Annual Meeting and nearly 50 publications at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) with its Simoa technology.
- Increased publications dramatically by 238, bringing the total to 600 (over 65 percent growth).
- Entered into multiple license and supply arrangements for access to Quanterix’ proprietary Nf-L antibodies. The Siemens Healthineers arrangement, marks a critical step toward a clinically relevant Nf-L test for patients. In the second arrangement, Quanterix will supply Nf-L antibodies to Bio-Techne.
- Extended the Company’s oncology footprint with the launch of the Simoa SP-X Imaging and Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu of additional multiplex panels, offering researchers a robust and highly-sensitive solution to test the efficacy and toxicity of immuno-oncology based therapeutics.
- Strengthened the Company’s leadership team with the election of Sarah Hlavinka to its Board of Directors, and hiring of Amol Chaubal as Chief Financial Officer, Tatiana Plavina, Ph.D.(formerly of Biogen) as Vice President of Clinical Biomarker Strategy, Hether Ide (formerly of Thermo Fisher Scientific) as Vice President of North American Sales, and Andy Keys (formerly of SomaLogic) as Vice President of Worldwide Pharma Service Sales.
- Moved to a new headquarters in Billerica, Mass., which contains the Company’s CLIA-certified lab, Simoa Accelerator Lab and expanding workforce under one roof.
- Was the lead sponsor of the fourth-annual Powering Precision Health Summit (PPH) held in Barcelona, a conference dedicated to addressing the critical role of biomarkers in eradicating diseases such as Alzheimer’s and cancer. The summit was sold out and created significant momentum for Quanterix products.
"This past year was a testament to what can be accomplished when you bring the right people, determination and technology together," continued Hrusovsky. "We are encouraged by how our growth catalysts have all lined up for 2020 and feel our market opportunity is compelling."
To access the live webcast of Quanterix’ presentation at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 4 p.m., PST, please visit https://jpmorgan.metameetings.net/events/hc20/sessions/29706-quanterix-corporation/webcast. To access the subsequent Q&A session with Hrusovsky on Wednesday, Jan. 15, 2020 at 4:30 p.m., PST, please visit https://jpmorgan.metameetings.net/events/hc20/sessions/30008-quanterix-corporation-q-a/webcast. Replays of the webcasts will be available for a limited period following the conference.
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Staci Didner, (407) 734-7325
Investor Relations Contact: